Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells.

[1]  K. Fujieda,et al.  Transforming growth factor-beta1 induces matrix metalloproteinase-9 expression in human meningeal cells via ERK and Smad pathways. , 2009, Biochemical and biophysical research communications.

[2]  Jeong Eon Lee,et al.  EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. , 2009, Cellular signalling.

[3]  M. Moasser,et al.  The epidermal growth factor receptor family: Biology driving targeted therapeutics , 2008, Cellular and Molecular Life Sciences.

[4]  K. Mohammad,et al.  Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. , 2007, Cancer research.

[5]  P. ten Dijke,et al.  The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. , 2006, Cancer research.

[6]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[7]  K. Miyazono,et al.  Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. , 2005, Journal of the National Cancer Institute.

[8]  L. Larue,et al.  Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo , 2005, Oncogene.

[9]  Wei He,et al.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Dohlman,et al.  MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. , 2005, Current opinion in chemical biology.

[11]  M. Björklund,et al.  Gelatinase-mediated migration and invasion of cancer cells. , 2005, Biochimica et biophysica acta.

[12]  S. Bao,et al.  The activation of Akt/PKB signaling pathway and cell survival , 2005, Journal of cellular and molecular medicine.

[13]  K. Choe,et al.  Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Tony Hunter,et al.  Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. , 2003, Cancer cell.

[15]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[16]  K. Flanders,et al.  Smad3: A Key Player in Pathogenetic Mechanisms Dependent on TGF‐β , 2003, Annals of the New York Academy of Sciences.

[17]  Koichi Hattori,et al.  Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases , 2003, Current opinion in hematology.

[18]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[19]  R. Herrmann,et al.  Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7 , 2001, Genes, chromosomes & cancer.

[20]  S. J. Chen,et al.  Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta. , 2000, Experimental cell research.

[21]  M. Bitzer,et al.  Smad3 and Smad4 Mediate Transcriptional Activation of the Human Smad7 Promoter by Transforming Growth Factor β* , 2000, The Journal of Biological Chemistry.

[22]  H. Modjtahedi,et al.  Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. , 2000, Cancer research.

[23]  L. Coussens,et al.  Extrinsic regulators of epithelial tumor progression: metalloproteinases. , 2000, Current opinion in genetics & development.

[24]  D. Crowe,et al.  Transcriptional inhibition of matrix metalloproteinase 9 (MMP-9) activity by a c-fos/estrogen receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion. , 1999, Neoplasia.

[25]  H. Friess,et al.  The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer , 1999, Oncogene.

[26]  J. Massagué,et al.  Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway , 1999, Nature.

[27]  M. Stack,et al.  Proteinase requirements of epidermal growth factor–induced ovarian cancer cell invasion , 1998, International journal of cancer.

[28]  C. Heldin,et al.  Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. , 1998, Biochemical and biophysical research communications.

[29]  A. Roberts,et al.  Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. , 1998, Genes & development.

[30]  T. Pawson,et al.  Signaling through scaffold, anchoring, and adaptor proteins. , 1997, Science.

[31]  R. Fridman,et al.  Epidermal growth factor and amphiregulin up‐regulate matrix metalloproteinase‐9 (MMP‐9) in human breast cancer cells , 1997, International journal of cancer.

[32]  G. Stark,et al.  Regulation of STAT‐dependent pathways by growth factors and cytokines , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[34]  J. Massagué,et al.  Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex , 1995, Molecular and cellular biology.

[35]  T. Tsuruo,et al.  Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. , 1993, Cancer research.

[36]  D. Crowe,et al.  Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. , 2001, Neoplasia.

[37]  Y. Yarden,et al.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.